CRMD Stock Summary and Trading Ideas (Cormedix | NASDAQ:CRMD)

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Cormedix trades on the NASDAQ stock market under the symbol CRMD.

As of April 2, 2026, CRMD stock price declined to $6.99 with 357,719 million shares trading.

CRMD has a beta of 1.29, meaning it tends to be more sensitive to market movements. CRMD has a correlation of 0.05 to the broad based SPY ETF.

CRMD has a market cap of $552.56 million. This is considered a Small Cap stock.

Last quarter Cormedix reported $129 million in Revenue and $.61 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.22.

In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.

The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, IWM, VXF, IWO, CALF.

CRMD has underperformed the market in the last year with a return of +15.2%, while the SPY ETF gained +18.0%. In the last 3 month period, CRMD fell short of the market, returning -39.9%, while SPY returned -3.7%. However, in the most recent 2 weeks CRMD has outperformed the stock market by returning +9.7%, while SPY returned -0.8%.

CRMD support price is $6.81 and resistance is $7.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.